Development of “Sharkavir”: A New Hypothetical Inhibitor for HIV-1 Protease

HIV has infected approximately 37 million people worldwide and results in over 1 million deaths annually. A key component of the HIV life cycle is the enzyme HIV-1 protease, which is involved in cutting newly made protein components of the HIV virion. Our research focused on how can molecular models be used to simulate the binding of various HIV-1 prtease inhibitors including Darunavir, Ritonavir, and a novel combination of these two named "Sharkavir".